Ethaverine and Papaverine Target Cyclin-Dependent Kinase 5 and Inhibit Lung Cancer Cell Proliferation and Migration

Area of Science:

• Molecular biology
• Oncology
• Pharmacology

Background:

• Cyclin-dependent kinase 5 (CDK5) is crucial for neuronal functions and implicated in neurodegenerative diseases and lung cancer.
• Existing ATP-competitive CDK5 inhibitors lack selectivity and have limitations, necessitating novel therapeutic strategies.
• Allosteric modulation represents a promising alternative approach for targeting CDK5.

Purpose of the Study:

• To identify and characterize novel allosteric modulators of CDK5.
• To evaluate the efficacy of ethaverine and papaverine in inhibiting non-small cell lung cancer (NSCLC) cell proliferation and migration.
• To investigate the potential of repurposing ethaverine and papaverine for lung cancer therapy.

Main Methods:

• High-throughput screening for allosteric CDK5 modulators.
• Cell proliferation and migration assays using NSCLC cell lines.
• Combination therapy studies with ethaverine/papaverine and roscovitine.
• In cellulo thermal denaturation assays and siRNA-mediated knockdown of CDK5.

Main Results:

• Ethaverine and papaverine were identified as allosteric inhibitors of CDK5.
• These compounds significantly inhibited proliferation and migration in NSCLC cell lines.
• Combined treatment with roscovitine demonstrated enhanced efficacy, suggesting an additive inhibitory mechanism.
• Thermodenaturation studies and siRNA experiments confirmed in cellulo interaction with CDK5.

Conclusions:

• Ethaverine and papaverine are effective allosteric inhibitors of CDK5.
• These compounds show significant potential for repurposing in lung cancer treatment.
• The dual mechanism involving ethaverine/papaverine and roscovitine offers a novel therapeutic strategy for CDK5-driven lung cancers.